RxDoctor Payments Data

Jeffrey Baron

Family · Winchester, INNPI 1750382446

Payments from drug & device makers

$1,912in general payments, 2019–2025

Across 89 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$741
  • AstraZeneca$276
  • Boston Scientific$206
  • Otsuka America Pharmaceutical, Inc.$148
  • Pfizer$112
  • Lilly USA, LLC$112
  • plus $318 from 8 others

What the payments were for

  • Food & beverage$1,912100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,912 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$86,679
Medicare patients
292
Services billed
1,669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$38,302
MounjaroTirzepatide24$27,961
OxycontinOxycodone Hcl13$25,883
FarxigaDapagliflozin Propanediol16$22,921
RybelsusSemaglutide16$21,897
EliquisApixaban24$19,509
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$19,373
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,249
TrintellixVortioxetine Hydrobromide14$6,375
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen163$4,753
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$4,276
VascepaIcosapent Ethyl11$3,690
Albuterol Sulfate HfaAlbuterol Sulfate108$2,784
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen82$1,763
Morphine Sulfate26$1,761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$57$60,19850 claims
AstraZenecaFarxiga, Breztri Aerosphere$276$31,17029 claims
Lilly USA, LLCMounjaro$112$27,96124 claims
PfizerEliquis$112$19,50924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in Winchester

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →